Effects of ospemifene on the female reproductive and urinary tracts

Translation from preclinical models into clinical evidence

David F. Archer, Bruce R. Carr, JoAnn V. Pinkerton, Hugh S. Taylor, Ginger D. Constantine

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women's health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy). Methods: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue. Results: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia). Conclusions: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).

Original languageEnglish (US)
Pages (from-to)786-796
Number of pages11
JournalMenopause
Volume22
Issue number7
DOIs
StatePublished - Jul 8 2015

Fingerprint

Urinary Tract
Estrogens
Atrophy
Tamoxifen
Estrogen Antagonists
Dyspareunia
Endometrial Hyperplasia
Selective Estrogen Receptor Modulators
Metrorrhagia
Vaginal Smears
Ospemifene
Women's Health
Vagina
Endometrial Neoplasms
Osteoporosis
Hormones
Breast Neoplasms
Hemorrhage
Safety
Estrogen Receptor Antagonists

Keywords

  • Dyspareunia
  • Endometrium
  • Estrogen receptor agonist/antagonist
  • Selective estrogen receptor modulator
  • Urinary tract
  • Vulvar and vaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Effects of ospemifene on the female reproductive and urinary tracts : Translation from preclinical models into clinical evidence. / Archer, David F.; Carr, Bruce R.; Pinkerton, JoAnn V.; Taylor, Hugh S.; Constantine, Ginger D.

In: Menopause, Vol. 22, No. 7, 08.07.2015, p. 786-796.

Research output: Contribution to journalArticle

Archer, David F. ; Carr, Bruce R. ; Pinkerton, JoAnn V. ; Taylor, Hugh S. ; Constantine, Ginger D. / Effects of ospemifene on the female reproductive and urinary tracts : Translation from preclinical models into clinical evidence. In: Menopause. 2015 ; Vol. 22, No. 7. pp. 786-796.
@article{c6c7c9d906194cb79c82482e691b2e77,
title = "Effects of ospemifene on the female reproductive and urinary tracts: Translation from preclinical models into clinical evidence",
abstract = "Objective: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women's health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy). Methods: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue. Results: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia). Conclusions: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).",
keywords = "Dyspareunia, Endometrium, Estrogen receptor agonist/antagonist, Selective estrogen receptor modulator, Urinary tract, Vulvar and vaginal atrophy",
author = "Archer, {David F.} and Carr, {Bruce R.} and Pinkerton, {JoAnn V.} and Taylor, {Hugh S.} and Constantine, {Ginger D.}",
year = "2015",
month = "7",
day = "8",
doi = "10.1097/GME.0000000000000365",
language = "English (US)",
volume = "22",
pages = "786--796",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Effects of ospemifene on the female reproductive and urinary tracts

T2 - Translation from preclinical models into clinical evidence

AU - Archer, David F.

AU - Carr, Bruce R.

AU - Pinkerton, JoAnn V.

AU - Taylor, Hugh S.

AU - Constantine, Ginger D.

PY - 2015/7/8

Y1 - 2015/7/8

N2 - Objective: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women's health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy). Methods: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue. Results: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia). Conclusions: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).

AB - Objective: Treatment of menopausal symptoms by compounds with tissue-selective estrogen agonist/antagonist effects, often called selective estrogen receptor modulators, has been researched as an alternative to the use of estrogen therapy. These structurally diverse molecules elicit tissue-dependent responses in hormone-responsive tissues and organs, exhibiting variations in estrogenic activity in preclinical models of postmenopausal reproductive tissues that may improve postmenopausal women's health (eg, prevention and treatment of breast cancer, osteoporosis, and vulvar and vaginal atrophy). Methods: This literature review investigates whether preclinical data predicted the clinical effects of ospemifene on female reproductive and urinary tract tissues and compares these findings with the specific vaginal effects of other estrogen receptor agonists/antagonists (tamoxifen, raloxifene, and bazedoxifene) in preclinical and clinical studies. Lasofoxifene, although not currently available, is included because of its unique effects on vaginal tissue. Results: The response of endometrial and vaginal tissues to estrogen receptor agonists/antagonists can be differentiated using transvaginal ultrasound, endometrial histopathology, cytologic examination of vaginal smears, assessment of physical changes in the vagina, and relief of symptoms associated with vulvar and vaginal atrophy (such as dyspareunia). Conclusions: Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists (eg, tamoxifen, raloxifene, and bazedoxifene) with no short-term concerns about endometrial safety (based on endometrial hyperplasia, carcinoma, endometrial spotting, and endometrial bleeding).

KW - Dyspareunia

KW - Endometrium

KW - Estrogen receptor agonist/antagonist

KW - Selective estrogen receptor modulator

KW - Urinary tract

KW - Vulvar and vaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84937072759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937072759&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000365

DO - 10.1097/GME.0000000000000365

M3 - Article

VL - 22

SP - 786

EP - 796

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 7

ER -